Knowledge Library
Evaluation of the efficacy of ADC in vitro and in vivo
Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, an ADC-derived monoclonal antibody is conjugated with cytotoxic agents (payloads) which can deliver potent cellular toxins to targeted cancer cells specifically. We have established a state-of-the-art platform …Read More >
Validation of GVHD in mouse model for preclinical efficacy screen
AACR Annual meeting 2021 Na Xu, Ya Zhang, Rou Xie, Lijun Jia, Yingying Cai, Qing Lin Oncology and Immunology Unit, WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China Background Bone marrow transplantation has been successfully and widely used to treat diseases such as leukemia and lymphomas. However, the complication Graft …Read More >
Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer
AACR Annual meeting 2021 Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec, Shanghai, China; 2 WuXi AppTec, Jiangsu, China Corresponding Author: Qunsheng Ji. Email: ji_qunsheng@wuxiapptec.com Background Many cancer types are driven by specific gene aberrances, like gene fusions, mutations and copy number changes. It has led to …Read More >
Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics
AACR Annual meeting 2021 Ting Ni, Zhixiang Zhang, Xuzhen Tang, Hui Qi, Jingying Zhang, Ke Mao, Wenting Shi, Qingyang Gu, Qunsheng Ji WuXi AppTec, Suzhou, China Abstract Recent advances in cancer biology and diagnosis are providing more targeted approaches to treat cancers. Therapy targeting the specific oncogenic driver could inhibit tumor progression and helps to …Read More >
Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies
Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >
Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors
Tumors are complex ecosystems composed of different cell types with different phenotypes, status and gene profiles. Commonly used GEP tools like bulk RNA Sequencing can only display gene expression profiles as a whole, and cannot reflect the heterogeneous tumor cell change or immune composition in a tumor. Single cell RNA sequencing is a good tool …Read More >
Identification of Tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren’s syndrome model in mice
Sjögren’s syndrome, which affects hundreds of millions of people worldwide, is a chronic autoimmune disorder characterized by leukocytic infiltration into the exocrine glands, such as the salivary and lacrimal glands. However, the pathological mechanism remains to be elucidated, and novel treatments are urgently needed. Over the past decade, extensive progress has been made in the …Read More >